Drug intelligence / Profile preview

AT-1902

Development stage: Preclinical
Lead developer: Novartis
Modality: Gene Therapies

Overview

AT-1902 is a gene therapy candidate developed by Anthos Therapeutics, which was later acquired by Novartis. It is currently in early clinical stages and is being investigated for the treatment of rare diseases. This acquisition by Novartis aims to expand its capabilities in rare diseases and gene therapy, integrating AT-1902 into its specialty pipeline.

Beyond the preview

Go deeper on AT-1902.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT-1902.

Explore the full profile